OncoCyte Corp represents a commitment to advancing the field of cancer diagnostics. The company’s corporate philosophy focuses on developing innovative solutions to improve the early detection and treatment of cancer. OncoCyte Corp values scientific excellence, collaboration, and integrity in its pursuit of reliable and accurate diagnostic technologies. By leveraging cutting-edge research and technologies, OncoCyte Corp aims to provide physicians and patients with actionable insights for more effective diagnosis and personalized treatment planning. With a dedication to improving patient outcomes, OncoCyte Corp strives to make a meaningful impact in the fight against cancer.

OncoCyte Corp, a leading biotechnology company, primarily operates in the United States. With its headquarters in Alameda, California, OncoCyte focuses on the development and commercialization of novel diagnostics for early detection and monitoring of cancer. The company leverages advanced technologies for the detection of biomarkers associated with various cancers, including lung and breast cancer. OncoCyte aims to provide innovative diagnostic solutions to improve patient outcomes and revolutionize cancer care.

OncoCyte Corp has achieved several significant milestones. The company successfully developed and launched the non-invasive test, DetermaVu, a diagnostic tool designed to detect lung cancer. OncoCyte Corp also received a Breakthrough Device designation from the FDA for DetermaVu. In addition, the company collaborated with several renowned institutions and organizations for further research and development. OncoCyte Corp's dedication to advancing cancer diagnostics has positioned it as a key player in the industry. With ongoing efforts, the company continues to contribute to improving the detection and treatment of lung cancer.

OncoCyte Corp is a biotechnology company specializing in the development and commercialization of novel molecular diagnostic tests for the early detection of cancer. Established in 2009, OncoCyte has been committed to revolutionizing cancer diagnosis through its advanced technology and innovative approach. The company's focus lies in leveraging the power of liquid biopsies and specialized tests to provide accurate, reliable, and non-invasive cancer screening solutions. OncoCyte Corp aims to improve patient outcomes by detecting cancer at its earliest stages when treatment options are most effective. With a strong dedication to research and development, OncoCyte Corp continues to make significant strides in the field of early cancer detection.

The main competitors of OncoCyte Corp in the market include companies such as Exact Sciences Corporation, Genomic Health Inc., and Veracyte Inc.

OncoCyte Corp is primarily active in the biotechnology industry.

OncoCyte Corp is a medical technology company focused on the development and commercialization of innovative diagnostic tests for early detection of cancer. The company's business model revolves around the research and development of novel liquid biopsy and blood-based tests that detect and analyze biomarkers associated with various types of cancers. OncoCyte Corp aims to provide accurate, non-invasive, and cost-effective diagnostic solutions to aid in the detection and monitoring of cancer, ultimately improving patient outcomes. Through their cutting-edge technology and ongoing research efforts, OncoCyte Corp seeks to revolutionize cancer detection and contribute to the advancement of personalized medicine.

Το OncoCyte P/E είναι -0,73.

Το KUV της εταιρείας OncoCyte είναι 44,84.

Το AlleAktien Qualitätsscore για το OncoCyte είναι 3/10.

Ο κύκλος εργασιών του αναμενόμενη OncoCyte είναι 499.950,00 USD.

Το αναμενόμενη OncoCyte κέρδος είναι -30,85 Εκ. USD.

OncoCyte is a biotechnology company specialized in the development of diagnostic tests for cancer. They focus on research and development of diagnostic tests, commercialization and marketing of these tests, and creating partnerships with other companies and research institutions. They use modern technologies such as molecular diagnostics, next-generation sequencing, and immunohistochemistry in their research and development. Their goal is to offer their test solutions in different markets and expand their distribution network through collaborations. They have developed the LungENT diagnostic test for lung cancer and the DetermaIO test for predicting response to immunotherapies.

Η OncoCyte καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το OncoCyte αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της OncoCyte είναι US68235C1071.

Το WKN της OncoCyte είναι A2ACBH.

Ο τίκερ της OncoCyte είναι OCX.

Κατά τους τελευταίους 12 μήνες η OncoCyte κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η OncoCyte προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της OncoCyte ανέρχεται σήμερα στο .

OncoCyte πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η OncoCyte πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το OncoCyte ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των OncoCyte από την 26/9/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 26/9/2024.

Η τελευταία μερίσματος έγινε στις 26/9/2024.

Το έτος 2023, η OncoCyte διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του OncoCyte καταβάλλονται σε USD.